Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish




Antibody Drug Conjugates

Technologies & Platforms

WuXi Biologics strength is its highly experienced leadership team. Each senior executive brings over 15 years of industry experience in biologics discovery, development, manufacturing and testing.

Chris Chen

Chris Chen, Ph.D.
Chief Executive Officer, Biologics Service

Over 15 years of experience in bioprocess development, scale-up, manufacturing and quality. Formerly CEO of Shanghai Kanda; COO of Shanghai Celgen; Director of Process Science & Production at AME (now Eli Lilly), Manager of BioProcess Technology at Merck. Ph.D. from University of Delaware.

Weichang Zhou

Weichang Zhou, Ph.D.
Chief Technology Officer, Biologics Development & Manufacturing

Over 20 years of biologics development and manufacturing experience. Previously Sr. Director of Commercial Cell Culture Development at Genzyme, Sr. Director of Process Sciences and Engineering at PDL Biopharma, and Associate Director of Fermentation and Cell Culture at Merck. Postdoc at University of Minnesota, DECHEMA and ETH Zurich. Ph.D. from University of Hannover, Germany.

Chiang Syin, Ph.D.
Chief Quality Officer

Over 29 years of experience in U.S. FDA regulatory review and GMP compliance of biological and biotech products including time as Branch Chief in the Office of Compliance and Biologics Quality, the Center for Biologics Evaluation and Research (CBER).  Prior to WuXi Biologics, he was a Gates Project International Expert for the Center of Food & Drug Inspection (CFDI) of CFDA. Dr. Syin received his Ph.D. in chemistry from the Catholic University of America and joined the U.S. FDA after his postdoctoral training at NIAID and the NIH.

Jing Li

Jing Li, Ph.D.
Vice President, Biologics Discovery

Over 19 years of experience in biologics discovery, strong experience in leading mab discovery projects from ideas to early clinical development at Novartis and Wyeth, program team leader for critical mab projects, formerly Assoc. Director at Novartis and Sr. Scientist at Wyeth. M.D., Ph.D. from Peking University and MBA from Yale University.

Wesley Wang

Wei-Chun (Wesley) Wang, Ph.D.
Vice President, Process Development

Over 24 years of process & product development experience in biopharmaceutical industry.  Previously Scientific Director, Commercial Analytical Science Team Leader at Amgen, Senior Scientist at Immunex and Senior Research Investigator at Bristol-Myers Squibb.  Ph.D. in Biochemistry from University of Georgia.

Gang Huang

Gang Huang, Ph.D.
Vice President, Analytical, Formulation & Regulatory

Over 16 years of industry experience in the U.S. including 14 years of biopharmaceutical experience at Amgen as Scientific Director in Process & Product Development. Leading cross-functional process and technology development teams and analytical development of innovative protein products and biosimilars. Ph.D. in analytical chemistry from Purdue.

Jian Dong

Jian Dong, MBA
VP & Site Head of Biomanufacturing

Over 25 years of experience in biomanufacturing, technology transfer, quality, and process development. Formerly Vice President at Unilab Bioscience and Celgen, Sr Process Engineer at Lilly.

Paul Liu

Paul Liu, Ph.D.
Vice President, Biosafety Testing

Over 25 years of experience in bioprocess development and GMP manufacturing in U.S. and China.  Previously with Merck and Nektar. Most recently was CTO at Livzon Mabpharm and CTO/Co-founder of Shanghai Henlius Biotech. Ph.D. in Chemical Engineering from University of Delaware.

Jerry Xu

Jerry Xu, Ph.D.
Vice President, Quality Assurance

25 years of experience in large and small molecule DS and DP, GMP QA and regulatory affairs. Previously with US FDA,  Wyeth/Pfizer, and Genzyme. Founded Shanghai Fleecon Biomedical Inc. in 1996 and served as President until 2001. Ph.D. from Northeastern University.

PK Tsai

PK Tsai, Ph.D.
Vice President, Alliance Management

Over 30 years of U.S. experience in Analytical Development and Quality Control of biologics and vaccines. Extensive experience in managing CROs. Formerly Sr. Investigator at Merck. Ph.D. from University of Minnesota.

DQ Wang, Ph.D.
Vice President, Formulation, Fill and Finish

Over 22 years of experience in FFF, scale-up, process transfer and production at Bayer Global Biologics. Obtained Ph.D. in Engineering from Oregon State University. Served as Chairman of Industrial Advisory Board for the U.S. National Science Foundation Research Center for Pharmaceutical Processing. Is an adjunct professor at Purdue University and Peking University. Former President of CABS (Chinese American BioPharmaceutical Society) in the US.

Liang Tang, Ph.D.
Vice President, Cell Culture Process Development

Over 27 years’ experience in protein therapeutic discovery and cell culture manufacturing process development. Formerly with Bayer Pharmaceuticals (USA) and Heska. Obtained Ph.D degree in protein biochemistry and molecular biology from McGill University, Canada and postdoctoral training, Imperial College of Science, Technology and Medicine, in London, UK.

Jill Cai
Vice President, Cell Line Development and Protein Sciences

Over 20 years of industry research and biologics product development experience. Formerly with Millennium (now Takeda), Abbott, and Amgen. Received MS degree from Wesleyan University.

Peter Shen
Vice President, Biologics and Bioprocess

Over 15 years of experience in process development, technical transfer, clinical manufacturing and process validation at both large pharma and CMO organizations.  Formerly with DuPont Pharma, Bristol-Myers Squibb, Johnson & Johnson, and Laureate Biopharma, Inc. Received MS degree in Biochemistry from New Mexico State University.

Jincai (Jimmy) Li, Ph.D.
Vice President, MFG 1, Biopharmaceuticals

Over 15 years of experience in process development, technology transfer and scale-up. Formerly with Genentech Inc., Tanox, Inc., and Diversa Corporation (now Verinium), Received Ph.D. degree in Chemical and Biochemical Engineering from University of Maryland Baltimore County.